BLRX - BioLineRx Ltd.
0.886 0.00 (0.15%)
After hours: 4:14PM EDT
| Previous Close | 0.886 |
| Open | 0.890 |
| Bid | 0.870 x 3000 |
| Ask | 0.960 x 1000 |
| Day's Range | 0.871 - 0.905 |
| 52 Week Range | 0.780 - 1.340 |
| Volume | 253,527 |
| Avg. Volume | 363,825 |
| Market Cap | 97.727M |
| Beta | 0.45 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.252 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.00 |
- ACCESSWIRE•7 days ago
Bioline RX Ltd Sponsored ADR to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 13, 2018 / Bioline RX Ltd Sponsored ADR (NASDAQ: BLRX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 13, 2018 at 10:00 AM ...
- PR Newswire•7 days ago
BioLineRx Reports Second Quarter 2018 Financial Results
TEL AVIV, Israel , Aug. 13, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results ...
- PR Newswire•13 days ago
BioLineRx Announces Positive Results of Lead-in Period for Phase 3 GENESIS Trial in Stem-Cell Mobilization
BioLineRx Ltd. (BLRX) (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today positive results from the lead-in period of the GENESIS trial, a double-blind, placebo-controlled Phase 3 trial comparing BL-8040 in combination with granulocyte colony-stimulating factor (G-CSF), to G-CSF alone, for the mobilization of hematopoietic stem cells (HSCs) used for autologous transplantation in multiple myeloma patients. The open-label, single-arm, lead-in period of the study was designed to include up to 30 patients, with Data Monitoring Committee (DMC) review after completion of approximately 10, 20 and 30 patients, in order to assess safety and efficacy following treatment with BL-8040 plus G-CSF.
- PR Newswire•14 days ago
BioLineRx to Report Second Quarter 2018 Results on August 13, 2018
TEL AVIV, Israel, Aug. 6, 2018 /PRNewswire/ -- BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today it will release its unaudited financial results for the quarter ended June 30, 2018 on Monday, August 13, 2018, before the US markets open. The Company will host a conference call on Monday, August 13, 2018 at 10:00 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer. The conference call will be available via webcast and can be accessed through the Investor Relations page of BioLineRx's website.
- PR Newswire•19 days ago
BioLineRx Initiates Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors
BioLineRx Ltd. (BLRX) (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it has initiated a Phase 1/2a clinical study for AGI-134, a novel compound that evokes a direct anti-tumor response, as well as a vaccine effect, via a unique, universally applicable, multi-arm mechanism that targets patient-specific tumor neoantigens. AGI-134 is a synthetic, intratumorally administered glycolipid designed to label cancer cells with alpha-Gal, which then become the target of pre-existing anti-Gal antibodies, effectively triggering an immediate local anti-tumor response, as well as a follow-on systemic anti-tumor response targeting both the primary injected tumor and distal secondary tumors. The study is primarily designed to evaluate the safety and tolerability of AGI-134, given both as monotherapy and in combination with an immune checkpoint inhibitor, in unresectable metastatic solid tumors.
- Benzinga•21 days ago
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Social Reality Inc (NASDAQ: SRAX ) stock was trading ...
- PR Newswire•21 days ago
BioLineRx Announces Expansion of Immuno-Oncology Collaboration in Pancreatic Cancer
TEL AVIV, Israel, July 30, 2018 /PRNewswire/ -- BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today the expansion of its immuno-oncology collaboration with Merck & Co., Inc., Kenilworth, N.J., USA (known as MSD outside the United States and Canada) for the support of a Phase 2a program investigating BioLineRx's BL-8040 in combination with KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy marketed by Merck & Co., Inc., Kenilworth, N.J., USA, in patients with metastatic pancreatic cancer. Under the expansion, a triple combination arm investigating the safety, tolerability and efficacy of BL-8040, KEYTRUDA and chemotherapy will be added to the ongoing COMBAT/KEYNOTE-202 study.
- Zacks•last month
CTI BioPharma Tanks Post Type B Talks on Pacritinib With FDA
CTI BioPharma (CTIC) conducts Type B meeting with the FDA to discuss a regulatory pathway for its lead pipeline candidate Pacritinib, currently under study for the treatment of myelofibrosis.
- Zacks•last month
Aclaris' Alopecia Candidate Gets Fast Track Designation
The FDA grants fast track status to Aclaris' (ACRS) JAK-inhibitor, ATI-502, for the treatment of alopecia areata.
- Benzinga•last month
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials
Biotech stocks held their ground in a holiday-shortened week amid a drought of market-moving catalysts. Looking ahead, the following are catalytic events for biotech investors to watch. Conferences Fourth ...
- Zacks•last month
Aclaris Stock Up on JAK Inhibitor's Encouraging Activity
Aclaris Therapeutics (ACRS) posts positive interim data from a phase II study on its Alopecia Areata candidate, ATI-502.
- Zacks•2 months ago
BioLineRx Sees Hammer Chart Pattern: Time to Buy?
BioLineRx Sees Hammer Chart Pattern: Time to Buy?
- Zacks•2 months ago
Shire (SHPG) HAE Drug Gets FDA Nod for Pediatric Population
Shire (SHPG) gains FDA approval for expanding the label of its hereditary angioedema (HAE) drug, Cinryze, to include its usage among pediatric patients aged six years and older.
- PR Newswire•2 months ago
BioLineRx Presents New Overall Survival Data From Phase 2a Study for BL-8040 in r/r AML Patients
TEL AVIV, Israel, June 18, 2018 /PRNewswire/ -- BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that new data presented at the 23rd Annual Congress of the European Hematology Association (EHA), held in Stockholm, Sweden, shows that BL-8040, combined with high dose cytarabine (HiDAC), significantly enhanced overall survival in difficult-to-treat relapsed or refractory AML (r/r AML) patients in a Phase 2a clinical trial.
- PR Newswire•2 months ago
BioLineRx to Participate at JMP Securities 2018 Life Sciences Conference
TEL AVIV, Israel , June 13, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that its Chief ...
- PR Newswire•3 months ago
BioLineRx Reports First Quarter 2018 Financial Results
TEL AVIV, Israel , May 22, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results ...
- PR Newswire•3 months ago
BioLineRx to Present Overall Survival Data at EHA from Phase 2a Study of BL-8040 in r/r AML Patients
BioLineRx Ltd. (BLRX) (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it will present data at the 23rd Annual Congress of the European Hematology Association (EHA), to be held June 14-17, 2018 in Stockholm, Sweden, showing that BL-8040, combined with high dose cytarabine (HiDAC), significantly enhanced overall survival of difficult-to-treat relapsed or refractory AML (r/r AML) patients in a Phase 2a clinical trial. Patients with r/r AML were treated daily with BL-8040 monotherapy for two days followed by combined administration of BL-8040 and HiDAC for 5 days for 1-2 cycles.
- ACCESSWIRE•3 months ago
Breakfast Technical Briefing on BioLine Rx and Three More Biotech Stocks
LONDON, UK / ACCESSWIRE / May 17, 2018/ If you want a free Stock Review on BLRX sign up now at www.wallstequities.com/registration. In today's pre-market research, WallStEquities.com evaluates Aratana Therapeutics Inc. (NASDAQ: PETX), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), BioDelivery Sciences International Inc. (NASDAQ: BDSI), and BioLine Rx Ltd (NASDAQ: BLRX).
- PR Newswire•3 months ago
BioLineRx Reports Results of Phase 2 Study for BL-8040 Monotherapy in Stem Cell Mobilization for Allogeneic Bone Marrow Transplantation
TEL AVIV, Israel, May 17, 2018 /PRNewswire/ -- BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today positive results from a Phase 2 clinical trial assessing BL-8040 as a single agent for hematopoietic stem cell mobilization in an allogeneic transplantation setting. Mobilization of hematopoietic stem and progenitor cells (HSPCs) for the purpose of donor (allogeneic) transplantation after high-dose chemotherapy is currently performed using a 4-5 day treatment cycle with G-CSF and a 1-2 day apheresis procedure. This proof-of-concept Phase 2 study, consisting of 24 donor/recipient pairs, assesses the ability of BL-8040 monotherapy to mobilize HSPCs for transplantation in a single administration.
- Benzinga•3 months ago
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Biolinerx Ltd/S ADR (NASDAQ: BLRX ) stock was trading ...
- PR Newswire•3 months ago
BioLineRx to Report First Quarter 2018 Results on May 22, 2018
Management to hold a conference call at 10:00 a.m. EDT TEL AVIV, Israel , May 16, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX)( TASE: BLRX)( BLRX) , a clinical-stage biopharmaceutical company focused ...
- PR Newswire•3 months ago
BioLineRx Announces Grant of European Patent Covering Use of BL-8040 with Cytarabine for Treating Acute Myeloid Leukemia
BioLineRx Ltd. (BLRX)(BLRX.TA)(BLRX) , a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that the European Patent Office (EPO) has issued a Decision to Grant a patent claiming the use of BL-8040 with cytarabine, a chemotherapeutic agent, for the treatment of acute myeloid leukemia (AML). This patent will be valid through March 2034, with the option of up to five years' patent term extension. Member patents were also granted in Japan and Hong Kong. Additional corresponding patent applications are pending in China (a Notice of Acceptance was received), Israel (a Notice of Acceptance was received), the United States, India, Korea, Mexico, Brazil, Canada and Australia.
- Zacks•5 months ago
Moving Average Crossover Alert: BioLineRx Ltd. (BLRX)
Moving Average Crossover Alert: BioLineRx Ltd. (BLRX)
- ACCESSWIRE•5 months ago
Wired News – vTv Therapeutics Completed Phase-1b Study Evaluating TTP399 for Treatment of Type-1 Diabetes
Stock Monitor: BioLine Rx Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 27, 2018 / Active-Investors.com has just released a free research report on vTv Therapeutics Inc. (NASDAQ: VTVT ). If you ...
- PR Newswire•5 months ago
BioLineRx Announces Notice of Allowance From USPTO for Patent Covering AGI-134 - a Novel Immunotherapy for Treating Solid Tumors
TEL AVIV, Israel, March 26, 2018 /PRNewswire/ -- BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that a Notice of Allowance has been issued by the United States Patent and Trademark Office (USPTO) for a patent application claiming the use of AGI-134, a novel immunotherapy compound, for the treatment of solid cancer tumors. This patent, when issued, will be valid until May 2035 with a possibility of up to five years patent term extension. Additional corresponding patent applications for AGI-134 are pending in Europe, Japan, China, Canada, Australia and Israel.
